| Literature DB >> 20225063 |
L R Ruhaak1, G Zauner, C Huhn, C Bruggink, A M Deelder, M Wuhrer.
Abstract
Most methods for the analysis ofEntities:
Mesh:
Substances:
Year: 2010 PMID: 20225063 PMCID: PMC2911528 DOI: 10.1007/s00216-010-3532-z
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.142
Fig. 1Strategies for N-glycan and O-glycan release from glycoproteins and glycopeptides
Fig. 2Labeling of glycans. a 2-Aminobenzoic acid (2-AA) labeling via reductive amination, b 1-phenyl-3-methyl-5-pyrazolone labeling via a Michael-type addition, c labeling with phenylhydrazide, and d glycan permethylation
Sample purification after glycan labeling
| Method | Material | Label | Comments | References |
|---|---|---|---|---|
| SPE | RP, C18 | RA, aniline | [ | |
| SPE | RP, C18 | Permethylation | TFA may be added | [ |
| SPE | RP, C18 | HL, BACH | [ | |
| SPE | PGC | RA, 2-AB | Sample application in water, elution using 25% (v/v) ACN | [ |
| SPE | PGC | RA, benzylamine | Sample application in water, elution using 20% (v/v) ACN | [ |
| SPE | HILIC, nylon filter, Oasis HLB or amide-2 | RA, 2-AA | Sample application in 95% ACN, elution using water | [ |
| SPE | HILIC, cellulose | RA, 2-AA | Sample application in 80% ACN, elution using water | [ |
| SPE | HILIC, microelution plate | RA, 2-AB | Sample application in 80% ACN, elution using water | [ |
| SPE | HILIC, DPA-6S | RA, APTS | Sample application in 90% ACN, elution using water | [ |
| Gel filtration | Sephadex G10 | RA, APTS | Gel filtration in 96-well format in filter plates | [ |
| Gel filtration | Toyopearl HW-40F | RA, APTS | [ | |
| Gel filtration | Sephadex G15 | RA, PA | [ | |
| Liquid–liquid extraction | Water/chloroform | Permethylation | Permethylated glycans are in the organic (lower) phase | [ |
| Liquid–liquid extraction | Water/dichloromethane | Permethylation | Permethylated glycans are in the organic (lower) phase | [ |
| Liquid–liquid extraction | Water/ethyl acetate | HL, phenylhydrazine | Labeled glycans are in the aqueous phase | [ |
| Liquid–liquid extraction | Water/butyl ether | MA, PMP | Labeled glycans are in the aqueous phase | [ |
| Liquid–liquid extraction | Water/chloroform | MA, PMP | Labeled glycans are in the aqueous phase | [ |
| Paper chromatography | 3 MM Whatman filter paper | RA, 2-AB, DAP | Glycans are eluted using water | [ |
| Precipitation | Acetone | RA, PA | Precipitation with water-free acetone was conducted 3 times | [ |
SPE solid-phase extraction, RP reverse phase, PGC porous graphitized carbon, HILIC hydrophilic interaction liquid chromatography, RA reductive amination, HL hydrazide labeling, BACH 6-(biotinyl)-aminocaproyl hydrazide, 2-AB 2-aminobenzamide, 2-AA 2-aminobenzoic acid, APTS 1-aminopyrene-3,6,8-trisulfonic acid, PA 2-aminopyridine, MA Michael addition, PMP 1-phenyl-3-methyl-5-pyrazolone, DAP 2,6-diaminopyridine, TFA trifluoroacetic acid, ACN acetonitrile
Some typical methods and applications of electromigrative separation techniques for oligosaccharide analysis
| Application | Derivatization | Separation technique | Detection | Background electrolyte | Comments | References |
|---|---|---|---|---|---|---|
|
| APTS | CGE | LIF 488 nm | POP-6 and POP-7 (Bio-Rad) | Sequencer technology | [ |
| Glycoprotein and glycan standards | APTS | CGE | LIF 488 nm | Polyacrylamide polymera in 89 mM Tris, 89 mM borate, 2.2 mM EDTA | Sequencer technology | [ |
| Exoglycosidases and standards for identification | ||||||
| Influenza A virus hemagglutinin | APTS | CGE | LIF 488 nm | POP-6 (Bio-Rad) | Sequencer technology | [ |
| Glycoprotein standards | APTS | CGE | LIF 488 nm | 25 mM acetate pH 4.75 with 0.4% PEOb | [ | |
| Recombinant monoclonal antibody | APTS | CGE | LIF 488 nm | Kit system based on gel electrophoresis | Coated capillary, enzymatic digestions for identification | [ |
| Glucose ladder standard | ANTS | CGE | LIF 325 nm | 25 mM ammonium acetate, 0–1% PEO (300,000) | Neutral capillary coating | [ |
| Glucose ladder standard, RNase B | APTS | CGE | LIF 488 nm | 25 mM ammonium acetate, 0-1% PEOb | Neutral capillary coating | [ |
| Fetuin | APTS | CGE | LIF 488 nm | 25 mM ammonium acetate, 0.4% PEO (300,000) | Neutral capillary coating, enzymatic digestions for identification | [ |
| α1-Acid glycoprotein | 2-AA | CGE | LIF 325 nm | 100 mM Tris–borate (pH 8.3), 10% PEG (70,000) | Neutral (DB-1) capillary | [ |
| Linkage differentiation | ||||||
| Monoclonal antibody | 2-AA | CGE | LIF 325 nm | 100 mM Tris–borate (pH 8.3), 10% PEG (35,000) | Neutral (DB-1) capillary | [ |
| Linkage differentiation | ||||||
| Antibody pharmaceuticals | 3-AA, APTS | CGE | LIF 488 and 325 nm | 3-AA: 100 mM Tris–borate pH 8.3 with 10% PEG (70,000) | Neutral (DB-1) capillary | [ |
| APTS: 50 mM Tris–acetate pH 7.0 with 0.5% PEG (70,000) | ||||||
| Serum IgG | APTS | CGE | LIF 488 nm | POP-7 gel buffer | Sequencer technology | [ |
| Clinical application | ||||||
| Fetuin | APTS | CGE | LIF 488 nm | 25 mM phosphate pH 2.5 or 25 mM acetate pH 4.75 with 0–0.8% PEO (300,000) | Neutral capillary coating | [ |
| Chondroitin sulfate type proteoglycans | 2-Aminoacridone | CGE | LIF 488 nm | 100 mM Tris–borate pH 8.0 with 1% PEG (70,000) or | Use of a neutral capillary coating | [ |
| 2-AA | LIF 325 nm | 100 mM Tris–borate pH 8.3 with 10% PEG 70,000 | ||||
| Chondroitine sulfate, trypsin inhibitor ulinastatin | None | MEKC, CGE | UV 214 nm | 50 mM borate pH 9.3, 100 mM SDS or | Partial use of a neutral capillary coating | [ |
| 2-Aminoacridone | LIF 488 nm | 100 mM Tris–borate pH 8.0 with 1% PEG (70,000) or | ||||
| 2-AA | LIF 325 nm | 100 mM Tris–borate pH 8.3 with 10% PEG (70,000) | ||||
| RNase B, hen egg albumin, bovine serum fetuin | 2-Aminoacridone | MEKC | LIF 488 nm | 500 mM sodium borate pH 8.87, 80 mM taurodeoxycholate | [ | |
| IgG | 2-Aminoacridone | MEKC | LIF 442 nm | 300 mM boric acid, 80 mM taurodeoxycholic acid, pH 9.2 (NaOH) | [ | |
| RNase B | 2-Aminoacridone | MEKC | LIF 442 nm | 300 mM boric acid , 80 mM taurodeoxycholic acid, pH 9.2 (NaOH) | [ | |
| Glycosaminoglycan disaccharides | 2-Aminoacridone, ANTS | FACE | Fluorescence | FACE carbohydrate analysis kit from Prozyme ( | [ | |
| RNase B, α1-acid glycoprotein | 2-AB | MEKC and CD-CE | UV 254 nm | 50 mM phosphate, 150 mM SDS, pH 6.7 or | [ | |
| 50 mM phosphate, pH 6.7 (NaOH/TEA), 4% SBE-γ-CD | ||||||
| Maltoheptaose standard, RNase B | APTS | CE and CGE | Off-line MALDI; UV 254 nm | 10 mM ammonium actetate pH 4.75 or | Neutral poly(vinyl alcohol) coating | [ |
| 25 mM ammonium acetate pH 4.75 with 0.4% PEOb | CE with fraction collector | |||||
| Fetuin, α1-acid glycoprotein, IgG, transferrin | 9-Fluorenylmethyl chloroformate | CE | MS | 50 mM ammonoium acetate | [ | |
| Maltose ladder standard | Aminonaphthalene monosulfonic, disulfonic, and trisulfonic acid | CE | UV 235 nm | 50 mM triethylammonium phosphate, pH 2.5 | Reverse EOF | [ |
| High-mannose | 6-Aminoquinoline, PA | CE | UV 240 nm | 100 mM sodium phosphate, 50 mmM Bu4N+, pH 5.0 | Polyether coating | [ |
| Dextran ladder, monosaccharides | APTS | CE | LIF 488 nm | 100 or 200 mM borate pH 10.2 or 50 mM phosphate pH 2.2 | Linkage differentiation | [ |
| Monclonal antibody characterization | APTS | CE | LIF 488 nm and MS | 40 mM EACA pH 4.5 (HOAc) | Hydroxypropylmethylcellulose or poly(vinyl alcohol) coating | [ |
| RNase B, asialofetuine, α1-acid glycoprotein | APTS | Chip-CE | LIF 488 nm | 1 mM phosphate, 20 mM HEPES, pH 6.8 | [ | |
| Cellobiohydrolase, RNase B | APTS | CE | MS | 25 mM ammonium acetate | Separation of phosphorylated isomers | [ |
| Dextran ladder | ANTS | CE | MS | 1% acetic acid/NH4OH, pH 3.4 | [ | |
| Standards, fetuin, ovalbumin | ANTS | CE | LIF 325 nm | 50 mM phosphate pH 2.5 | [ | |
| Standards and beverages | None | CE | Amperometric | 100 mM NaOH | [ | |
| Wine samples | None | CE | MS | 300 mM diethylamine | [ | |
| Fetuin, α1-acid glycoprotein, erythropoietin | None | CE | MS | 100 mM EACA, 900 mM NH3, 70% MeOH | MS/MS characterization | [ |
| Disaccharide standards | None | CE | Indirect UV 400 nm; or direct UV 195 nm | 6 mM | Borate complexation | [ |
| Mono- and disaccharides | None | CEC | MS | Acetonitrile/water/ammonium formate mobile phase | [ | |
|
| None | CEC | MS | 2.4 mM ammonium acetate pH 3, 0.2 mM sodium acetate in 50:50 acetonitrile/water | Desialylation prior to analysis | [ |
| RNase B, human milk bile salt-stimulated lipase | None | CEC | MS | Acetonitrile/water/ammonium formate mobile phase | MS/MS characterization | [ |
| RNase B | 2-AB | CEC | LIF 325 nm | Acetonitrile/water/ammonium formate mobile phase | [ | |
| α1-Acid glycoprotein, ovalbumin | 2-AB | CEC | UV 210 nm | Acetonitrile/water/ammonium formate mobile phase, sulfated β-CD | [ |
ANTS 2-aminonaphthalene trisulfonic acid, GCE capillary gel electrophoresis, MEKC micellar electrokinetic chromatography, FACE fluorescence-assisted carbohydrate electrophoresis, CD cyclodextrin, CE capillary electrophoresis, LIF laser-induced fluorescence, MALDI matrix-assisted laser desorption/ionization, MS mass spectrometry, Tris tris(hydroxymethyl)aminomethane, PEO poly(etheylene oxide), PEG poly(ethylene glycol), 3-AA 3-aminobenzoic acid, SDS sodium dodecyl sulfate, TEA tetraethylammonium, SBE sulfobutyl ether, EACA ε-aminocaproic acid, HEPES N-(2-hydroxyethyl)piperazine-N′-ethanesulfonic acid, EOF electroosmotic flow
a12% solution of acrylamide/bisacrylamide (19:1) polymerized with ammonium persulfate and N,N,N′,N′-tetramethylethylenediamine
bMolecular weight not stated
Fig. 3Separation of 1-aminopyrene-3,6,8-trisulfonic acid labeled glycans on a microfluidic device in 1 mM phosphate and 20 mM N-(2-hydroxyethyl)piperazine-N′-ethanesulfonic acid pH 6.8. Glycans were released from a blood sample of a stage IV breast cancer patient. (Taken from [103] with permission)
Fig. 4Subfemtomole sensitivity of nanoscale liquid chromatography (LC)–electrospray ionization (ESI)–mass spectrometry (MS) in the analysis of a 2-aminobenzamide (2-AB)-labeled hexamannosidic N-glycan (Man6GlcNAc2). A 2-AB-labeled hexamannosidic N-glycan was analyzed using nanoscale hydrophilic interaction LC (HILIC)–ESI–ion trap–MS. Base-peak chromatograms of a dilution series show that the detection of as little as 2 fmol of 2-AB-tagged Man6GlcNAc2 injected is possible (A). Sum mass spectra of the elution range of Man6GlcNAc2 (25.2–26 min; B–E) revealed the detection of proton adducts (m/z 1,517) and sodium adducts (m/z 1,539) down to 0.5 fmol of injected standard (E). Combined selected ion chromatograms for m/z 1,517 and m/z 1,539 allowed the detection of the standard after injection of a 2-fmol as well as a 0.5-fmol aliquot (inset in A). (Reproduced from [159] with permission)
Fig. 5Mixed-mode HILIC/anion exchange separation of α1-acid glycoprotein oligosaccharides before (a) and after (b) desialylation. S1−S5 refer to the number of sialic acid residues present in the oligosaccharides. Bi, Tri, Tri + F, Tetra, and Tetra + F refer to biantennary, triantennary, fucosylated triantennary, tetraantennary, and fucosylated tetraantennary N-linked oligosaccharides, respectively. (Reproduced from [166] from with permission)
Fig. 6Analysis of N-linked oligosaccharides from human α1-acid glycoprotein. 2-AB-labeled oligosaccharides obtained were analyzed by high-pH anion-exchange chromatography with fluorescence detection (a) or high-performance LC (HPLC) with an amide-80 column and fluorescence detection (b). (Reproduced from [168] with permission)
Fig. 7Reverse-phase HPLC with fluorescence detection of 2-AB-labeled glycans released from a 10 μg RNase B, b 30 μg ovalbumin, and c 30 μg fetuin. The structures of the labeled oligosaccharide peaks are shown in d. Species that were coeluted in the same fluorescence peak are indicated by letters a and b. The peaks corresponding to the species that were eluted early (less than 20 min) containing two or more sialic acids are not shown. Circles mannose, squares GlcNAc, diamonds galactose, triangles fucose, stars sialic acid, dashed lines α linkage, solid lines β linkage, vertical lines 1–2 linkage, horizontal lines 1–4 linkage, forward slashes 1–3 linkage, backslashes 1–6 linkage; wavy lines unknown linkage. (Reproduced from [180] with permission)
Fig. 8Analysis of 2-AA-labeled total plasma N-glycans by matrix-assisted laser desorption/ionization (MALDI)–Fourier transform ion cyclotron resonance (FTICR)–MS. Samples were prepared as described previously [34], desalted by porous graphitized carbon solid-phase extraction, and analyzed by MALDI-FTICR-MS using a 2,5-dihydroxybenzoic acid matrix. The low-mass range (top) and the high-mass range (bottom) were measured using different ion-transfer times. The inset shows the isotope pattern of registered glycan species. Yellow circles galactose, green circles mannose, blue squares N-acetylglucosamine, purple diamonds sialic acid, red triangles fucose
Fig. 9A natural glycan microarray approach with reductively aminated glycans. a Glycans are derivatized, b fractionated by HPLC, c analyzed by MALDI time of flight MS(/MS), d immobilized on microarray epoxide slides, e assayed for protein interaction, and f the data obtained are interpreted. (Reproduced from [202] with permission)